EasyMotion Tec AG
Successful approval of the securities prospectus

THE INFORMATION CONTAINED IN THIS DOCUMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, NEITHER IN WHOLE NOR IN PART, TO, WITHIN OR FROM THE UNITED STATES OF AMERICA OR ANY OTHER COUNTRY WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD CONSTITUTE A VIOLATION OF THE LAWS OF SUCH COUNTRY.

The listing of EasyMotionSkin Tec AG is planned for December 9

– Public offering of 10,000 shares on the day of the initial listing

– Listing to take place in the m:access trading segment of the Munich Stock Exchange

Vaduz/Triesen, December 02, 2021. EasyMotionSkin Tec AG (EasyMotionSkin), a leading provider in the market of training and fitness systems using electromuscular stimulation (EMS), is expected to be listed on the Munich Stock Exchange from December 09, 2021.

Together with its subsidiaries, the company produces and distributes EMS training systems consisting of a suit, PowerBox and an app solution for training programs. The EasyMotionSkin systems have distinct advantages over conventional EMS training equipment: The patented dry electrode in the suit sets new standards in wearing comfort. All EasyMotionSkin systems work wirelessly – an innovation that enables flexible use. Users are no longer tied exclusively to studios; they can train independently of time and space.

The listing of EasyMotionSkin is planned in the m:access trading segment within over-the-counter market of the Munich Stock Exchange. A corresponding application for inclusion of the shares has been submitted to the Munich Stock Exchange. The securities prospectus has been reviewed by the German Federal Financial Supervisory Authority (“BaFin”) for completeness, coherence and comprehensibility and has already been approved. The public offering of a total of 10,000 shares will take place exclusively on the day of the initial listing, presumably on December 09, 2021.

Currently, EasyMotionSkin is mainly in the media due to the ESA space mission “Cosmic Kiss”. German astronaut Matthias Maurer is using the EasyMotionSkin training system to combat muscle atrophy and bone loss during his stay on the ISS space station. The project is scientifically managed by the Center for Space Medicine at the Charité in Berlin.

“We are entering new dimensions with our innovations. Electromuscular stimulation is becoming suitable for everyday use – for everyone to use flexibly in terms of time and space. In this way, we are making a contribution to the health and well-being of every individual” explains Jürgen Baltes, CEO of EasyMotionSkin Tec AG.

The securities prospectus is available for download on the issuer’s homepage (www.ems.ag) within the section “Public Offering”. In addition, the information below (“Disclaimer”) must be observed.

About EasyMotionSkin Tec AG:

EasyMotionSkin Tec AG is the parent company of the global operating EasyMotionSkin group. As the “smallest fitness studio in the world”, EasyMotionSkin offers beginners and
athletes a sophisticated EMS training system. Patented dry electrodes in an EMS suit
stimulate up to 90% of the body’s muscles with low-frequency electrical impulses and thus
ensure increased oxygen intake, increased performance, optimal training effects and
regeneration. The basis for this trademarked high-tech product is the know-how of a leading
cardiac medic from Germany as well as acknowledged patient studies that verifiably prove
the positive effects. EasyMotionSkin is a premium product, developed and produced in
Germany. The core market is currently the DACH-region. Initial sales concepts exist in selected third countries. By using digitization and developing further product innovations, EasyMotionSkin Tec AG
spans the curve from an innovative fitness system manufacturer to a future-oriented tech
company in the international health and lifestyle industry.

Contact:

Jürgen Baltes (CEO)

mail: ir@ems.ag

Disclaimer

This publication does not constitute an offer. In particular, it does not constitute a public offer to sell or an offer, or a solicitation of an offer, to acquire, purchase or subscribe for shares or any other securities. The offer is based exclusively on the securities prospectus approved by the German Federal Financial Supervisory Authority (BaFin) on 2 December 2021 and published on EasyMotionSkin Tec AG’s website (www.ems.ag) in the “Public Offering” section. Only the securities prospectus contains the information for investors required by law.

Investors are recommended to carefully read the securities prospectus, which has been reviewed for completeness, coherence and comprehensibility by the German Federal Financial Supervisory Authority (BaFin) which is available on EasyMotionSkin Tec AG’s website (www.ems.ag) in the “Public Offering” section, before deciding to purchase or sell shares in EasyMotionSkin Tec AG in order to fully understand the potential risks and opportunities of the investment decision, and to make an investment decision only on the basis of all available information about the company after consulting their own lawyers, tax advisors and/or financial advisors. It is noted that an approval of the securities prospectus by BaFin is not to be construed as an endorsement of the relevant securities.

A public offering of the securities mentioned in this publication will be made exclusively on the basis of and in accordance with the securities prospectus and only in the Federal Republic of Germany. In particular, neither a public offer nor a solicitation of an offer to purchase any securities will be made in the United States of America, Japan, Canada, New Zealand or Australia.

The securities mentioned in this publication are, and will be, registered neither under the U.S. Securities Act of 1933 (the “Securities Act”) nor with any securities regulatory authority of any individual states of the United States of America. Unless a registration has been obtained, or exemptions from the registration requirements apply, under the U.S. Securities Act or the laws of an individual state of the United States of America, or relating to a transaction not subject to the U.S. Securities Act and in any event in accordance with the relevant laws of the individual states of the United States of America, the securities mentioned in this publication must not be (neither directly nor indirectly) offered, exercised, sold, pledged, transferred, or delivered within or to the United States of America or to, or on behalf of, or to the benefit of, a U.S. person (as defined in Regulation S under the Securities Act).

This publication may contain future-oriented statements. Future-oriented statements are all statements that do not refer to historical facts or events. This applies in particular to statements about the intentions, beliefs or current expectations of the company with respect to its future financial performance, plans, liquidity, prospects, growth, strategy and profitability as well as the economic environment in which the company operates. The future-oriented statements are based on current assessments and assumptions made by the company to the best of its knowledge. However, such future-oriented statements are subject to risks and uncertainties because they relate to future events and are based on assumptions that may not occur in the future. The company is not obligated to update or modify the future-oriented statements contained in this publication to reflect events or circumstances occurring after the date of this publication, unless such events or circumstances constitute an insider information subject to publication requirements.